Stifel Nicolaus reiterated their hold rating on shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in a research report released on Friday morning. Stifel Nicolaus currently has a $120.00 price target on the medical equipment provider’s stock.

Several other analysts have also recently weighed in on the company. Jefferies Group LLC reissued a buy rating and set a $136.00 price target on shares of Zimmer Biomet Holdings in a report on Friday. Morgan Stanley dropped their price target on Zimmer Biomet Holdings from $146.00 to $136.00 and set an overweight rating for the company in a report on Thursday. BMO Capital Markets dropped their price target on Zimmer Biomet Holdings from $140.00 to $135.00 and set an outperform rating for the company in a report on Thursday. Piper Jaffray Companies cut Zimmer Biomet Holdings from an overweight rating to a neutral rating in a report on Thursday. Finally, SunTrust Banks, Inc. set a $136.00 price target on Zimmer Biomet Holdings and gave the stock a buy rating in a report on Wednesday, November 1st. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus price target of $134.75.

Shares of Zimmer Biomet Holdings (ZBH) opened at $109.25 on Friday. Zimmer Biomet Holdings has a 52-week low of $95.63 and a 52-week high of $133.49. The stock has a market capitalization of $22,089.91, a P/E ratio of 13.54, a PEG ratio of 1.48 and a beta of 1.17. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.47 and a quick ratio of 0.80.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). The business had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet Holdings had a net margin of 8.36% and a return on equity of 16.29%. The business’s quarterly revenue was down .8% on a year-over-year basis. During the same period in the previous year, the business earned $1.79 earnings per share. sell-side analysts anticipate that Zimmer Biomet Holdings will post 8.04 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Stifel Nicolaus Reaffirms Hold Rating for Zimmer Biomet Holdings, Inc. (ZBH)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.watchlistnews.com/stifel-nicolaus-reaffirms-hold-rating-for-zimmer-biomet-holdings-inc-zbh/1682105.html.

Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. increased its stake in shares of Zimmer Biomet Holdings by 4.1% in the 2nd quarter. BlackRock Inc. now owns 17,419,463 shares of the medical equipment provider’s stock valued at $2,236,657,000 after purchasing an additional 679,080 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Zimmer Biomet Holdings by 2.6% in the 2nd quarter. Vanguard Group Inc. now owns 13,380,517 shares of the medical equipment provider’s stock valued at $1,718,057,000 after purchasing an additional 339,106 shares during the last quarter. State Street Corp increased its stake in shares of Zimmer Biomet Holdings by 2.4% in the 1st quarter. State Street Corp now owns 8,193,165 shares of the medical equipment provider’s stock valued at $1,000,463,000 after purchasing an additional 191,747 shares during the last quarter. Longview Partners Guernsey LTD increased its stake in shares of Zimmer Biomet Holdings by 17.7% in the 3rd quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock valued at $878,958,000 after purchasing an additional 1,128,973 shares during the last quarter. Finally, American Century Companies Inc. increased its stake in shares of Zimmer Biomet Holdings by 8.1% in the 3rd quarter. American Century Companies Inc. now owns 4,165,353 shares of the medical equipment provider’s stock valued at $487,721,000 after purchasing an additional 311,654 shares during the last quarter. Institutional investors own 85.26% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.